40+ Presentations from Top Biopharma in 2022

Producing Challenging Protein Targets for Drug Discovery

Bryony Ackroyd, PhD, Senior Protein Scientist, Discovery Biology & Discovery Sciences R&D, AstraZeneca


Direct Tie2 Agonists Promote Vascular Stability for the Intravitreal Treatment of Diabetic Macular Edema

Nicholas Agard, PhD, Principal Scientist, Antibody Engineering, Genentech, Inc.


Exploring in silico Approaches for Antibody Drug Conjugates Developability Assessments

Marc Bailly, PhD, Principal Scientist, MSD


Highly Concentrated SubQ Formulations and Tackling Protein Aggregation

Karoline B. Bechtold-Peters, PhD, Senior Strategy & Technology Leader, Pharmaceuticals & Biopharma Process, Novartis Pharma


Long-Term Stability Predictions of Therapeutic Proteins in Solution from Short-Term Stability Data

Matjaz Boncina, PhD, Scientist, Biologics Drug Product, Technical Research and Development, Global Drug Development, Novartis


Analytical Ultracentrifugation as a Multi-Attribute Release and Characterization Method for AAV-Based Products

George Bou-Assaf, PhD, Scientist, Analytical Development – Product & Technology Development, Biogen


Optimization of Antibody Discovery from Multiomic Single-Cell B Cell Dataset

Adrian Carr, PhD, Data Science Team Leader Kymab, Sanofi


Overcoming Safety and Efficacy Challenges of Dual Checkpoint Inhibitor Combinations

Jonathan D. Cheng, Senior Vice President & Therapeutic Area Head, Oncology Clinical Development, Bristol Myers Squibb Co.


Accelerating Drug Discovery: A Refresh of the Lead Panel Generation Phase within Biopharm Discovery

Edward Coulstock, PhD, Associate Fellow & Scientific Leader, BMPD MDE, GlaxoSmithKline


The Polysorbate Challenges in Biotherapeutic Formulations – Digging into the Mechanism of Metal-Catalyzed Oxidation of PS80 & mAb to Develop Mitigations

Camille Dagallier, PhD, Senior Formulation Scientist, Biologics Drug Product Development & Manufacturing, Sanofi R&D


Combining Mammalian Libraries and Microfluidics for Versatile Antibody Hit Discovery and Optimization

Achim Doerner, PhD, Principal Scientist, Protein Engineering & Antibody Technologies, Merck Healthcare KGaA


AAV and mRNA Delivery of VHH Intrabodies for in vivo Targeting of Intracellular Proteins

Erwin De Genst, PhD, Senior Research Scientist, AstraZeneca


Biophysical and Functional Characterisation of IgG1 Antibodies with Engineered Hexamerization Propensity

Simone De Haij, PhD, Director Functional Characterization & Bioassays, Genmab BV


Multiplex Digital PCR, an Analytical Method for Gene Therapy, Delivering a Broad Versatile and Meaningful Readout

Peter Eisenhut, PhD, Research Investigator CMC, Takeda


In silico Approaches towards Developability Assessment and Optimization of NBEs

Andreas Evers, PhD, Principal Scientist, Computational Chemistry & Biology, Global Research & Development Discovery Technology, Merck Healthcare KGaA


Development Considerations of New Modalities

Achim Frauenschuh, Group Head, Late Stage Purification Process Development, Novartis Pharma


Harmonised MAM Platform across Sanofi CMC Development Sites for Process Support and Characterization

Yann Fromentin, Team Manager, High Throughput Analysis & Biopharmaceutical Development, Sanofi


From Data to Predictions: Virtual Screening for Multi-Specific Protein Therapeutics

Norbert Furtmann, PhD, Head, Computational & High-Throughput Protein Engineering, Large Molecule Research, Sanofi


Identifying and Validating Novel Oncology ADC Targets

Maria Groves, PhD, Director and Head of the Antibody Alliance Laboratory, AstraZeneca


Developability Profiling in Lead Discovery: Keeping the Funnel Wider for Longer

Emma R. Harding, PhD, Director & Head, Molecular Design & Engineering, GlaxoSmithKline


A Cell-based Receptor Discovery Platform Enables the Identification of Host Factors Specifically Targeted by the SARS CoV-2 Spike

Bushra Husain, PhD, Lab Head, Biologics, Bayer Pharma


Immunotherapy of Cancer in the Adjuvant Setting

Nageatte Ibrahim, MD, VP, Oncology & Global Clinical Development, MSD


A Rapid and Routine-Friendly Multi-Attribute Method (MAM) for the Monitoring of Critical Quality Attributes in Biotherapeutic Monoclonal Antibodies

Somar Khalil, PhD, Scientist, Analytical Development Sciences for Biologicals, UCB


The Emerging Use of Kinase Inhibitors for the Mitigation of T Cell Bispecific (TCB) Antibody-Induced Cytokine Release

Gabrielle Leclercq, PhD, Postdoctoral Scientist, Pharma Research & Early Development, Roche


Development of New Methods for Characterization of Antibody Self-Association and Non-Specificity

Nikolai Lorenzen, PhD, Principal Scientist, Biophysics and Injectable Formulation, Novo Nordisk


Nanobody®-Based T Cell Engagers

Paolo Meoni, PhD, Distinguished Scientist & Project Head, Sanofi


A Cost-of-Goods Modelling Analysis Comparing a Novel Cell-Free Platform to a Conventional Cell-Based Bioprocess for the Production of Highly Potent Neurotoxins

Williams Olughu, PhD, Principal Scientist, Ipsen


3D-DLS: Benchmarking an Optical Microrheological Viscometer for Biologics Development

Joy Puthawala, Principal Research Associate, Sanofi


Towards ML-Based Multi-Specific Antibody Optimization

Katrin Reichel, PhD, Senior Data Scientist, Computational & HT Protein Engineering, R&D Biologics Research/Protein Therapeutics, Sanofi


Generation of Superior Host Cell Lines for Biomanufacturing Using Plasmid Design & Cell Line Engineering Technologies

Anett Ritter, PhD, Investigator III, Cell Line Screening & Development, Novartis Pharma


Suitability of Transiently Expressed Antibodies for Clinical Studies

Sara Rodriguez Conde, PhD, Associate Director, Cell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca


CD19-Targeted Affinity-Reduced CD28-Bispecific Antibody Enhances and Prolongs Anti-Tumor Activity of Glofitamab

Johannes Sam, PhD, Principal Scientist & Group Leader, Roche Innovation Center Zurich


Impact of Conjugation Site Selection & Method on the Stability and PK of ADCs

Christian A. Schroeter, PhD, Associate Director, ADCs & Targeted NBE Therapeutics, Merck KGaA


Understanding Protein-Protein Interaction in Protein Coformulation Drug Product

Jing Song, Associate Principal Scientist, Materials and Biophysical Characterization, AR&D, MSD


Discovery and Characterisation of the CD96 Antibody GSK6097608, a High-Affinity, Antagonistic Anti-CD96 Antibody for Cancer Immunotherapy

Sarah Stuart, PhD, Team Leader, Biopharm Discovery, GlaxoSmithKline


Enhancing Endogenous and Synthetic Immunity with Engineered Antibody-Fusion Proteins for Cancer Immunotherapy

Pablo Umaña, PhD, Head, Cancer Immunotherapy Discovery, Roche


New Technologies for High-Throughput Screening of Membrane Protein Targets

Erik Vernet, PhD, Director, Antibody Technology, Novo Nordisk


Discovery of Antibodies against a Complex Target

Trevor Wattam, PhD, Scientific Leader, Antibody Discovery, GlaxoSmithKline


Building Analytical Platform to Enable Efficient Drug Development

Bernice Yeung, PhD, Head of Analytical Development (Chemistry), Biogen


Development of Potent Antagonist Against Target-of-Interest with Phage-Displayed Alternative Scaffolds

Yingnan Zhang, PhD, Senior Scientific Manager, Early Discovery Biochemistry, Genentech, Inc.


Generation and Engineering of Mono- and Bispecific Cattle-Derived Ultralong CDR-H3 Antibodies by Yeast Surface Display

Stefan Zielonka, PhD, Protein Engineering & Antibody Technologies, Merck KGaA


* As of 23 August. Please see individual agenda pages for most up-to-date agenda.